This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Histone Methyltransferases: Global Markets For Research Tools, Diagnostics And Drug Discovery

NEW YORK, April 3, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery

http://www.reportlinker.com/p01155360/Histone-Methyltransferases-Global-Markets-for-Research-Tools-Diagnostics-and-Drug-Discovery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

REPORT SCOPE INTRODUCTION STUDY GOALS AND OBJECTIVESThis BCC Research report, Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery, provides an overview of the current overall state of the histone methyltransferases market, focusing specifically on tools and reagents, drug discovery trends and diagnostic potential. It describes existing platforms and technologies on the market, and a detailed analysis of the competitive environments, including new trends and segments for novel products and assay development. This study includes information about significant players, trends, and obstacles and other information affecting this market and its different sectors. Overall, this report will forecast current and future trends and developments in the histone methyltransferases segment and its potential market and partnerships for 2013 to 2018.

REASONS FOR DOING THIS STUDYEpigenetics is defined as the study of heritable changes in gene expression caused by modifications other than changes in the DNA sequence. In eukaryotes, genomic DNA is packaged with histone proteins into the cell nucleus as chromatin. Examples of such modifications are DNA methylation and various histone modifications, both of which regulate gene expression without altering the underlying DNA sequence. Consequently, such modifications are not only important for proper development but can cause many pathological conditions including cancer.Epigenetics is a very complex scientific discipline. It includes many molecular "players" essential for proper cell function. During the last decade, substantial efforts in epigenetics drug discovery were made. Today, the market for epigenetic therapeutics was evaluated by some analysts at over $600 million, based on sales of four products: Dacogen from Eisai, Vidaza and Istodax from Celgene, and Zolinza from Merck, which target two epigenetic pathways-DNA methyltransferases (DNMT) and histone deacteylases (HDAC).Histone methyltransferases are another group of important epigenetic enzymes responsible for proper gene expression and silencing. For example, Ezh2 is one of the most well-studied histone methyltransferases. Over the past decade, it was deregulated in a variety of human cancers. Recently, the company Epizyme published a study in Nature Chemical Biology[1] where the Ezh2 inhibitor EPZ005687 was revealed. Moreover, other studies have shown that this large family of proteins can serve as an excellent predictive biomarker and target for diagnostics products development.Overall, the discovery of novel potent inhibitors for the histone methyltransferases family gives hope for many stagnated pharmaceutical R&D programs. The discovery of novel drug candidates for proteins, such as Ezh2, opens enormous possibilities not only in oncology research but in stem cell biology, neurodegeneration and other diseases.In summary, this report will focus on recent developments in the assay and reagents sector for methyltransferase studies, diagnostics products based on histone methylation research and drug candidates targeting histone methyltransferase activity. It will describe in detail market participants in research and products development, and overall collaborations between different pharma/biotech companies during last two to three years. This report will evaluate the current situation and forecast possible outcomes of histone methyltransferases assay/reagents development, diagnostics and therapeutics field for the next five years.

SCOPE AND FORMATThis report is essentially a business tool that can help market players properly evaluate new commercial opportunities in the epigenetic-related space of the histone methyltransferases segment in the context of research tools, diagnostics and therapeutics submarkets. The geographic scope of this study is global. This market is generally complex and consists of a number of different segments, each of which is affected differently by scientific and technological developments. This report identifies the main positive and negative factors affecting each segment, and forecasts market growth, future trends and product development in every major segment of this market.

METHODOLOGY AND INFORMATION SOURCESBoth primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on drug discovery and already marketed products was conducted. These secondary sources included drug discovery and science-related journals, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted.In a second phase, a series of semistructured interviews was conducted with company representatives, bench scientists, marketing representatives and other personnel at biotechnology and pharmaceutical companies. Other sources included academics, technology and consulting companies. Subsequent analysis of the documents and interviews notes was iterative.

INTENDED AUDIENCEThis report is intended for business development professionals, entrepreneurs and other investors who need to fully understand and properly evaluate each segment in the market for histone methyltransferases research and development. It provides insights into the market position of major companies, and shows new opportunities otherwise overlooked or less known to the business community. ANALYST CREDENTIALSDr. Marianna Tcherpakov has more than eight years of experience as a bench scientist specializing in biochemistry, cell biology and industrial assay development. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments. REPORT HIGHLIGHTSThis report provides:• An overview of the global market and commercial potential for histone methyltransferases (HMTs)• Analyses of global market trends, with data for 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018• Discussion of the history of epigenetics, descriptions of main epigenetic enzymes, targets for HMTs, the importance of HMTs in different cellular functions, and the role of HMTs in different diseases• Market participants providing reagent and assay for HMT research, and estimates and evaluation in research tool development• Patent analysis in HMT assay development• Current pipelines and drug candidates in HMT drug discovery• Comprehensive company profiles of major players.

TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 2STUDY GOALS AND OBJECTIVES 2REASONS FOR DOING THIS STUDY 2SCOPE AND FORMAT 3METHODOLOGY AND INFORMATION SOURCES 3INTENDED AUDIENCE 3ANALYST CREDENTIALS 3RELATED BCC REPORTS 4BCC ONLINE SERVICES 4DISCLAIMER 4 CHAPTER 2 SUMMARY 6SUMMARY TABLE GLOBAL MARKET FOR HISTONE METHYLTRANSFERASESRESEARCH AND DEVELOPMENT, THROUGH 2018 ($ MILLIONS) 7SUMMARY FIGURE GLOBAL MARKET FOR HISTONE METHYLTRANSFERASESRESEARCH AND DEVELOPMENT, 2011-2018 ($ MILLIONS) 7 CHAPTER 3 INTRODUCTION TO HISTONE METHYLTRANSFERASES RESEARCHAND PRODUCT DEVELOPMENT 10OVERVIEW 10DNA METHYLATION 12DNA METHYLTRANSFERASES 13DNA METHYLATION DETECTION TECHNIQUES 14HISTONE MODIFICATIONS 15TABLE 1 DIFFERENT CLASSES OF MODIFICATIONS IDENTIFIED ONHISTONES 15TABLE 2 MAIN CATEGORIES IN HISTONE-MODIFICATION ENZYMES 16CHROMATIN METHYLATION REACTION 17FIGURE 1 SCHEMATIC PRESENTATION OF METHYLATION REACTION 17HISTONE METHYLTRANSFERASES: LYSINE METHYLATION 18TABLE 3 EXAMPLES OF HISTONE LYSINE METHYLATION AND ITSFUNCTIONAL OUTCOMES 19Role of Lysine Methylation in Chromatin Transcription 20HISTONE METHYLTRANSFERASES: ARGENINE METHYLATION 20TABLE 4 EXAMPLES OF HISTONE ARGININE METHYLATION AND ITSFUNCTIONAL OUTCOMES 22Role of Arginine Methylation in Chromatin Transcription 22PRDM FAMILY AND HISTONE METHYLTRANSFERASE ACTIVITY 23TABLE 5 PRDM FAMILY MEMBERS, THEIR RELATED ENZYMATIC ACTIVITYAND BINDING PARTNERS 24TABLE 6 EXAMPLES OF EPIGENETIC ALTERATIONS IN DIFFERENTPATHOLOGIES 25 CHAPTER 4 DEVELOPMENT OF RESEARCH TOOLS AND REAGENTS FORHISTONE METHYLTRANSFERASES STUDIES AND PRODUCT DEVELOPMENT 27OVERVIEW 27TABLE 7 PERCENTAGE OF COMMERCIAL KITS GENERALLY PURCHASED FOREPIGENETIC RESEARCH (%) 28TABLE 8 SELECT SUPPLIERS OF EPIGENETIC PRODUCTS 29REAGENTS AND ASSAYS REQUIRED FOR HISTONEMETHYLTRANSFERASES (HMT) STUDIES 30TABLE 9 PRODUCT CATEGORIES FOR HMT RESEARCH, COMPANIESMARKETING THE PRODUCTS AND AVERAGE PRICES 32ANTIBODIES FOR HMT RESEARCH 32TABLE 10 GLOBAL MARKET FOR ANTIBODIES BY INDUSTRY SEGMENT,THROUGH 2016 ($ BILLIONS) 33TABLE 11 DISTRIBUTION OF VARIOUS APPLICATIONS FOR ANTIBODIES AS ARESEARCH TOOL (%) 33TABLE 12 MAIN MARKET PARTICIPANTS IN RESEARCH ANTIBODY SEGMENTAND THEIR RELATIVE MARKET SHARES (%) 34TABLE 13 SOURCES OF ANTIBODIES SUPPLY FOR RESEARCH AND THEIRPERCENTAGE ON THE MARKET 35PRODUCTION OF PROTEIN AND ENZYMES FOR HMT RESEARCH 36TABLE 14 PERCENTAGE USE OF SPECIFIC PROTEIN EXPRESSIONTECHNIQUES (%) 37TABLE 15 GLOBAL MARKET FOR PROTEIN CHROMATOGRAPHY, THROUGH2016 ($ MILLIONS) 38TABLE 16 AVERAGE SPENDING PER SCIENTIST ON PURIFICATION ANDSEPARATION PRODUCTS (%) 39TABLE 17 GLOBAL MARKET SHARES OF RECOMBINANT ENZYME MARKETBY DIFFERENT TYPE OF ENZYME IN 2012 (%) 40TABLE 18 GLOBAL RECOMBINANT ENZYME MARKET SHARES BY CUSTOMER(%) 41TABLE 19 LIST OF LYSINE HISTONE METHYLTRANSFERASES (KMT) ANDTHEIR SUBSTRATES 41TABLE 20 LIST OF LYSINE HISTONE DEMETHYLASES (KDM) AND THEIRSUBSTRATES 43TABLE 21 LIST OF ARGININE HISTONE METHYLTRANSFERASES AND THEIRSUBSTRATES 44MODULATORS AND INHIBITORS FOR HMT STUDIES 45TABLE 22 LIST OF INHIBITORS USED IN HISTONE METHYLTRANSFERASERESEARCH AND PRODUCT DEVELOPMENT 46SUBSTRATES USED IN HMTS ASSAYS 47TABLE 23 SUBSTRATES FOR HMTS FOR IN VITRO STUDIES ANDPERCENTAGE OF THEIR USE (%) 47IN VITRO ASSAY DEVELOPMENT MARKET FOR HMTS 48TABLE 24 SELECT IN VITRO ASSAY AND COMMERCIAL KIT PROVIDERS 49FIGURE 2 SCHEMATIC REPRESENTATION OF HMTS ASSAY DEVELOPMENT 49TABLE 25 LIST OF DIFFERENT ASSAY SET-UPS FOR HMT ACTIVITYMEASUREMENTS 51Selected Market Participants in Assay Development for HMTActivity 52Perkin Elmer 52G Bioscience 53Epigentek 54Cayman Chemical 54BPS Bioscience 54Reaction Biology 55BellBrook Labs 55Abcam 55CisBio Bioassays 55TABLE 26 SURVEY OF SCIENTISTS' OPINIONS ABOUT EPIGENETICSSCREENING IN DRUG DISCOVERY (%) 57TABLE 27 STUDIES AND ASSAY DEVELOPMENT IN SPECIFIC DISEASE AREAS(%) 57Active Motif 58Biocius 59BPS Bioscience 59Cayman Chemical 60EMD Millipore 60Epigentek 61Life Technologies 61Perkin Elmer 61Reaction Biology 62TABLE 28 GLOBAL MARKET FOR RESEARCH TOOLS, REAGENTS AND ASSAYSFOR HISTONE METHYLTRANSFERASE STUDIES, THROUGH 2018 ($MILLIONS) 63FIGURE 3 GLOBAL MARKET FOR RESEARCH TOOLS, REAGENTS AND ASSAYSFOR HISTONE METHYLTRANSFERASE STUDIES, 2011-2018 ($ MILLIONS) 63 CHAPTER 5 HISTONE METHYLTRANSFERASES IN DRUG DISCOVERY ANDTHERAPEUTICS DEVELOPMENT 65OVERVIEW 65TABLE 29 ALTERED HISTONE MODIFICATIONS IN DIFFERENTPATHOLOGICAL CONDITIONS 65TABLE 30 CURRENT APPROVED EPIGENETIC DRUGS ON THE MARKET 66ZOLINZA 66TABLE 31 SALES OF ZOLINZA, 2008-2010, ($ MILLIONS) 67ISTODAX 67TABLE 32 SALES OF ISTODAX, 2011 AND 2012 ($ MILLIONS) 68VIDAZA 68TABLE 33 SALES OF VIDAZA, 2010-2012 ($ MILLIONS) 69DACOGEN 69TABLE 34 SALES OF DACOGEN, 2009-2011 ($ MILLIONS) 70TABLE 35 EXAMPLES OF EPIGENETIC DRUG DISCOVERY PROGRAMS 71MARKET PARTICIPANTS IN THE HMT DRUG DISCOVERY SECTOR 73CELLCENTRIC 73CELLZOME (GSK) 76CONSTELLATION PHARMACEUTICALS 77DOMAINEX 78EPITHERAPEUTICS APS 79EPIZYME 80TABLE 36 COMPANIES DEVELOPING THERAPEUTICS WITH HISTONEMETHYLTRANSFERASE AS A DRUG DISCOVERY TARGET 82CURRENT DRUG CANDIDATES AND HMT INHIBITORS IN DEVELOPMENT 83TABLE 37 RECENT DRUG DISCOVERY DEVELOPMENTS FOR HISTONEMETHYLTRANSFERASE INHIBITORS 84G9A AND GLP INHIBITORS 85DOT1L INHIBITORS 86SMYD2 INHIBITORS 88EZH2 INHIBITORS 89SET7/9 INHIBITORS 91INHIBITORS FOR PRMT4 93ADDITIONAL HMTS AS DRUG DISCOVERY TARGETS 94Nsd 2/WHSC1 94MLL 94Set8 95Suv39H1 95TABLE 38 POTENTIAL MARKETS FOR HMTS DRUG DISCOVERY ($ BILLIONS) 96DEALS IN THE EPIGENETICS SECTOR AS INDICATORS FOR MARKETDEVELOPMENT AND ACTIVITY 96TABLE 39 DEALS IN EPIGENETICS MARKET IN THE LAST DECADE 96TABLE 40 YEAR AND FUNDING AMOUNT FOR EPIGENETIC COMPANIES INHMT DRUG DISCOVERY 102TABLE 41 GLOBAL DRUG DISCOVERY MARKET VALUE FOR HISTONEMETHYLTRANSFERASE RESEARCH, THROUGH 2018 ($ MILLIONS) 103FIGURE 4 GLOBAL DRUG DISCOVERY MARKET VALUE FOR HISTONEMETHYLTRANSFERASE RESEARCH, 2011-2018 ($ MILLIONS) 103ADDITIONAL DRUG DISCOVERY TARGETS RELATED TO HMT RESEARCH 103TABLE 42 POTENTIAL EPIGENTICS TARGETS FOR DRUG DISCOVERY:EPIGENETIC ENZYMES CLASSES IMPORTANT IN COVALENT MODIFICATIONOF DNA OR HISTONES 103HISTONE DEMETHYLASES AS DRUG TARGETS AND THEIR IMPACTON HMT ACTIVITY 104TABLE 43 RELATIONSHIP BETWEEN DEMETHYLASES,METHYLTRASNFERASES AND THEIR RESPECTIVE HISTONE METHYLATIONSITES 108CHROMATIN READERS AS DRUG TARGETS AND THEIR IMPACT ONHMT ACTIVITY 108TABLE 44 RELATIONSHIP BETWEEN HISTONE METHYLATION, METHYLREADERS AND THEIR FUNCTIONS 109 CHAPTER 6 HISTONE METHYLTRANSFERASES IN DIAGNOSTICS ANDBIOMARKER DEVELOPMENT 114OVERVIEW 114TABLE 45 NUMBER OF PUBMED PUBLICATIONS ON BIOMARKERS USINGDIFFERENT EPIGENETIC MECHANISMS, 2012 114TABLE 46 DNA METHYLATION EVENTS AND THEIR RELATION TODIFFERENT PATHOLOGIES 115TABLE 47 NUMBER OF PUBLICATIONS IN HISTONE METHYLATION AREABASED ON DIFFERENT SEARCH CRITERIA 118TABLE 48 RELATIONSHIP BETWEEN HISTONE METHYLATION AND CANCERPROGNOSIS 119LUNG CANCER AND HISTONE MODIFICATIONS 120PROSTATE CANCER AND HISTONE MODIFICATIONS 120BREAST CANCER AND HISTONE MODIFICATIONS 121LEUKEMIA AND HISTONE MODIFICATIONS 121ESOPHAGEAL AND GASTRIC CANCERS AND HISTONE MODIFICATIONS 121HISTONE MODIFICATIONS IN KIDNEY, LIVER AND PANCREATICCANCERS 122TABLE 49 DIFFERENT HISTONE METHYLTRANSFERASES AND THEIRASSOCIATION TO CANCER DEVELOPMENT 124TABLE 50 DEMETHYLASES AND THEIR ASSOCIATIONS WITH CANCERDEVELOPMENT 127TABLE 51 GLOBAL BIOMARKERS MARKET, THROUGH 2015 ($ BILLIONS) 129MARKET PARTICIPANTS IN EPIGENETIC DIAGNOSTICS SPACE 129TABLE 52 SELECT EPIGENTICS DIANGOSTICS COMPANIES 129DIAGENODE 131EPIGENOMICS AG 131EPIONTIS 133EXACT SCIENCES 134MDXHEALTH (FORMERLY ONCOMETHYLOME SCIENCES) 134ORION GENOMICS 135OXFORD BIODYNAMICS 136PROGNOSDX 137RIBOMED BIOTECHNOLOGIES 138SEQUENOM 139VOLITIONRX 140TABLE 53 EXAMPLES OF AVERAGE REVENUES IN EPIGENETIC DIAGNOSTICSCOMPANIES 141TABLE 54 GLOBAL MARKET FOR HISTONE METHYLATION IN BIOMARKERSAND DIAGNOSTICS PRODUCT DEVELOPMENT, THROUGH 2018 ($ MILLIONS) 143FIGURE 5 GLOBAL MARKET FOR HISTONE METHYLATION IN BIOMARKERSAND DIAGNOSTICS PRODUCT DEVELOPMENT, 2011-2018 ($ MILLIONS) 143TABLE 55 DIAGNOSTICS MARKET VALUES IN ONCOLOGY SECTOR, 2013 ($BILLIONS) 144 CHAPTER 7 IMPORTANCE OF PATENTS IN HISTONE METHYLTRANSFERASERESEARCH AND PRODUCT DEVELOPMENT 146TABLE 56 WORLDWIDE PATENTS AND PATENT APPLICATION SEARCH INHISTONE METHYLTRANSFERASE RESEARCH USING SPECIFIC KEYWORDS(NO. OF PATENTS) 146TABLE 57 WORLDWIDE SEARCH FOR NUMBER OF PATENTS AND PATENTAPPLICATIONS IN HISTONE METHYLTRANSFERASE RESEARCH ACCORDINGTO ASSIGNEE 148 CHAPTER 8 MARKET SUMMARY 150TABLE 58 NUMBER OF PUBLICATIONS USING HISTONEMETHYLTRANSFERASE AS SEARCH, 2000-2012 150FIGURE 6 NUMBER OF PUBLICATIONS FROM 2000-2012 USING HISTONEMETHYLTRANSFERASE AS SEARCH 150TABLE 59 DISTRIBUTION OF DRUG DEVELOPMENT PROGRAMS INEPIGENETIC SPACE (%) 151TABLE 60 GLOBAL MARKET FOR HISTONE METHYLTRANSFERASESRESEARCH AND DEVELOPMENT, THROUGH 2018 ($ MILLIONS) 152FIGURE 7 GLOBAL MARKET FOR HISTONE METHYLTRANSFERASESRESEARCH AND DEVELOPMENT, 2011-2018 ($ MILLIONS) 153TABLE 61 EXAMPLES OF MARKET PARTICIPANTS IN HISTONEMETHYLTRANSFERASE SECTOR AND THEIR REPRESENTATIVE PRODUCTS 153 CHAPTER 9 PROFILES OF SELECT COMPANIES 156CELLCENTRIC LTD. 156CONSTELLATION PHARMACEUTICALS 157DOMAINEX 158EPITHERAPEUTICS APS 160EPIZYME, INC. 161EISAI CO., LTD. 162GLAXOSMITHKLINE (GSK) 163 CHAPTER 10 LIST OF COMPANIES MENTIONED IN REPORT 167ABCAM 167ACTIVE MOTIF 167ANASPEC 167BELLBROOK LABS 167BOEHRINGER INGELHEIM GMBH 167CAYMAN CHEMICAL COMPANY 167CELGENE CORPORATION 168CELLCENTRIC LTD. 168CELL SIGNALING TECHNOLOGY, INC. 168CISBIO US 168CONSTELLATION PHARMACEUTICALS 168DIAGENODE INC. USA 168DOMAINEX 169EISAI CO., LTD. 169EMD GROUP (EMD MILLIPORE) 169ENZO LIFE SCIENCES, INC. 169EPIGENOMICS AG 169EPIGENTEK GROUP INC. 169EPITHERAPEUTICS APS 170EPIZYME, INC. 170EXACT SCIENCES CORPORATION 170G-BIOSCIENCES 170GSK US 170JOHNSON & JOHNSON 170LIFE TECHNOLOGIES CORP. 171MDXHEALTH, INC 171MERCK CORPORATE HEADQUARTERS 171METHYLGENE INC. 171NEW ENGLAND BIOLABS 171NOVARTIS INTERNATIONAL AG 171ORION GENOMICS 172PERKIN ELMER 172PFIZER 172PHARMACYCLICS, INC 172PROGNOSDX HEALTH, INC. 172RANA THERAPEUTICS INC. 172REACTION BIOLOGY CORP. 173RIBOMED BIOTECHNOLOGIES, INC. 173SEQUENOM, INC. 173SIGMA-ALDRICH 173SIRTRIS 173SYNDAX PHARMACEUTICALS, INC. 173TAKEDA PHARMACEUTICALS U.S.A., INC. 174THERMO FISHER SCIENTIFIC, INC. 174VOLITIONRX 174ZYMO RESEARCH CORPORATION 174

LIST OF TABLESSUMMARY TABLE GLOBAL MARKET FOR HISTONE METHYLTRANSFERASESRESEARCH AND DEVELOPMENT, THROUGH 2018 ($ MILLIONS) 7TABLE 1 DIFFERENT CLASSES OF MODIFICATIONS IDENTIFIED ON HISTONES 15TABLE 2 MAIN CATEGORIES IN HISTONE-MODIFICATION ENZYMES 16TABLE 3 EXAMPLES OF HISTONE LYSINE METHYLATION AND ITSFUNCTIONAL OUTCOMES 19TABLE 4 EXAMPLES OF HISTONE ARGININE METHYLATION AND ITSFUNCTIONAL OUTCOMES 22TABLE 5 PRDM FAMILY MEMBERS, THEIR RELATED ENZYMATIC ACTIVITYAND BINDING PARTNERS 24TABLE 6 EXAMPLES OF EPIGENETIC ALTERATIONS IN DIFFERENTPATHOLOGIES 25TABLE 7 PERCENTAGE OF COMMERCIAL KITS GENERALLY PURCHASED FOREPIGENETIC RESEARCH (%) 28TABLE 8 SELECT SUPPLIERS OF EPIGENETIC PRODUCTS 29TABLE 9 PRODUCT CATEGORIES FOR HMT RESEARCH, COMPANIESMARKETING THE PRODUCTS AND AVERAGE PRICES 32TABLE 10 GLOBAL MARKET FOR ANTIBODIES BY INDUSTRY SEGMENT,THROUGH 2016 ($ BILLIONS) 33TABLE 11 DISTRIBUTION OF VARIOUS APPLICATIONS FOR ANTIBODIES AS ARESEARCH TOOL (%) 33TABLE 12 MAIN MARKET PARTICIPANTS IN RESEARCH ANTIBODY SEGMENTAND THEIR RELATIVE MARKET SHARES (%) 34TABLE 13 SOURCES OF ANTIBODIES SUPPLY FOR RESEARCH AND THEIRPERCENTAGE ON THE MARKET 35TABLE 14 PERCENTAGE USE OF SPECIFIC PROTEIN EXPRESSIONTECHNIQUES (%) 37TABLE 15 GLOBAL MARKET FOR PROTEIN CHROMATOGRAPHY, THROUGH2016 ($ MILLIONS) 38TABLE 16 AVERAGE SPENDING PER SCIENTIST ON PURIFICATION ANDSEPARATION PRODUCTS (%) 39TABLE 17 GLOBAL MARKET SHARES OF RECOMBINANT ENZYME MARKET BYDIFFERENT TYPE OF ENZYME IN 2012 (%) 40TABLE 18 GLOBAL RECOMBINANT ENZYME MARKET SHARES BY CUSTOMER(%) 41TABLE 19 LIST OF LYSINE HISTONE METHYLTRANSFERASES (KMT) ANDTHEIR SUBSTRATES 41TABLE 20 LIST OF LYSINE HISTONE DEMETHYLASES (KDM) AND THEIRSUBSTRATES 43TABLE 21 LIST OF ARGININE HISTONE METHYLTRANSFERASES AND THEIRSUBSTRATES 44TABLE 22 LIST OF INHIBITORS USED IN HISTONE METHYLTRANSFERASERESEARCH AND PRODUCT DEVELOPMENT 46TABLE 23 SUBSTRATES FOR HMTS FOR IN VITRO STUDIES AND PERCENTAGEOF THEIR USE (%) 47TABLE 24 SELECT IN VITRO ASSAY AND COMMERCIAL KIT PROVIDERS 49TABLE 25 LIST OF DIFFERENT ASSAY SET-UPS FOR HMT ACTIVITYMEASUREMENTS 51TABLE 26 SURVEY OF SCIENTISTS' OPINIONS ABOUT EPIGENETICSSCREENING IN DRUG DISCOVERY (%) 57TABLE 27 STUDIES AND ASSAY DEVELOPMENT IN SPECIFIC DISEASE AREAS(%) 57TABLE 28 GLOBAL MARKET FOR RESEARCH TOOLS, REAGENTS AND ASSAYSFOR HISTONE METHYLTRANSFERASE STUDIES, THROUGH 2018 ($ MILLIONS) 63TABLE 29 ALTERED HISTONE MODIFICATIONS IN DIFFERENT PATHOLOGICALCONDITIONS 65TABLE 30 CURRENT APPROVED EPIGENETIC DRUGS ON THE MARKET 66TABLE 31 SALES OF ZOLINZA, 2008-2010, ($ MILLIONS) 67TABLE 32 SALES OF ISTODAX, 2011 AND 2012 ($ MILLIONS) 68TABLE 33 SALES OF VIDAZA, 2010-2012 ($ MILLIONS) 69TABLE 34 SALES OF DACOGEN, 2009-2011 ($ MILLIONS) 70TABLE 35 EXAMPLES OF EPIGENETIC DRUG DISCOVERY PROGRAMS 71TABLE 36 COMPANIES DEVELOPING THERAPEUTICS WITH HISTONEMETHYLTRANSFERASE AS A DRUG DISCOVERY TARGET 82TABLE 37 RECENT DRUG DISCOVERY DEVELOPMENTS FOR HISTONEMETHYLTRANSFERASE INHIBITORS 84TABLE 38 POTENTIAL MARKETS FOR HMTS DRUG DISCOVERY ($ BILLIONS) 96TABLE 39 DEALS IN EPIGENETICS MARKET IN THE LAST DECADE 96TABLE 40 YEAR AND FUNDING AMOUNT FOR EPIGENETIC COMPANIES INHMT DRUG DISCOVERY 102TABLE 41 GLOBAL DRUG DISCOVERY MARKET VALUE FOR HISTONEMETHYLTRANSFERASE RESEARCH, THROUGH 2018 ($ MILLIONS) 103TABLE 42 POTENTIAL EPIGENTICS TARGETS FOR DRUG DISCOVERY:EPIGENETIC ENZYMES CLASSES IMPORTANT IN COVALENT MODIFICATIONOF DNA OR HISTONES 103TABLE 43 RELATIONSHIP BETWEEN DEMETHYLASES,METHYLTRASNFERASES AND THEIR RESPECTIVE HISTONE METHYLATIONSITES 108TABLE 44 RELATIONSHIP BETWEEN HISTONE METHYLATION, METHYLREADERS AND THEIR FUNCTIONS 109TABLE 45 NUMBER OF PUBMED PUBLICATIONS ON BIOMARKERS USINGDIFFERENT EPIGENETIC MECHANISMS, 2012 114TABLE 46 DNA METHYLATION EVENTS AND THEIR RELATION TO DIFFERENTPATHOLOGIES 115TABLE 47 NUMBER OF PUBLICATIONS IN HISTONE METHYLATION AREABASED ON DIFFERENT SEARCH CRITERIA 118TABLE 48 RELATIONSHIP BETWEEN HISTONE METHYLATION AND CANCERPROGNOSIS 119TABLE 49 DIFFERENT HISTONE METHYLTRANSFERASES AND THEIRASSOCIATION TO CANCER DEVELOPMENT 124TABLE 50 DEMETHYLASES AND THEIR ASSOCIATIONS WITH CANCERDEVELOPMENT 127TABLE 51 GLOBAL BIOMARKERS MARKET, THROUGH 2015 ($ BILLIONS) 129TABLE 52 SELECT EPIGENTICS DIANGOSTICS COMPANIES 129TABLE 53 EXAMPLES OF AVERAGE REVENUES IN EPIGENETIC DIAGNOSTICSCOMPANIES 141TABLE 54 GLOBAL MARKET FOR HISTONE METHYLATION IN BIOMARKERSAND DIAGNOSTICS PRODUCT DEVELOPMENT, THROUGH 2018 ($ MILLIONS) 143TABLE 55 DIAGNOSTICS MARKET VALUES IN ONCOLOGY SECTOR, 2013 ($BILLIONS) 144TABLE 56 WORLDWIDE PATENTS AND PATENT APPLICATION SEARCH INHISTONE METHYLTRANSFERASE RESEARCH USING SPECIFIC KEYWORDS(NO. OF PATENTS) 146TABLE 57 WORLDWIDE SEARCH FOR NUMBER OF PATENTS AND PATENTAPPLICATIONS IN HISTONE METHYLTRANSFERASE RESEARCH ACCORDINGTO ASSIGNEE 148TABLE 58 NUMBER OF PUBLICATIONS USING HISTONEMETHYLTRANSFERASE AS SEARCH, 2000-2012 150TABLE 59 DISTRIBUTION OF DRUG DEVELOPMENT PROGRAMS INEPIGENETIC SPACE (%) 151TABLE 60 GLOBAL MARKET FOR HISTONE METHYLTRANSFERASESRESEARCH AND DEVELOPMENT, THROUGH 2018 ($ MILLIONS) 152TABLE 61 EXAMPLES OF MARKET PARTICIPANTS IN HISTONEMETHYLTRANSFERASE SECTOR AND THEIR REPRESENTATIVE PRODUCTS 153

LIST OF FIGURESSUMMARY FIGURE GLOBAL MARKET FOR HISTONE METHYLTRANSFERASESRESEARCH AND DEVELOPMENT, 2011-2018 ($ MILLIONS) 7FIGURE 1 SCHEMATIC PRESENTATION OF METHYLATION REACTION 17FIGURE 2 SCHEMATIC REPRESENTATION OF HMTS ASSAY DEVELOPMENT 49FIGURE 3 GLOBAL MARKET FOR RESEARCH TOOLS, REAGENTS AND ASSAYSFOR HISTONE METHYLTRANSFERASE STUDIES, 2011-2018 ($ MILLIONS) 63FIGURE 4 GLOBAL DRUG DISCOVERY MARKET VALUE FOR HISTONEMETHYLTRANSFERASE RESEARCH, 2011-2018 ($ MILLIONS) 103FIGURE 5 GLOBAL MARKET FOR HISTONE METHYLATION IN BIOMARKERSAND DIAGNOSTICS PRODUCT DEVELOPMENT, 2011-2018 ($ MILLIONS) 143FIGURE 6 NUMBER OF PUBLICATIONS FROM 2000-2012 USING HISTONEMETHYLTRANSFERASE AS SEARCH 150FIGURE 7 GLOBAL MARKET FOR HISTONE METHYLTRANSFERASESRESEARCH AND DEVELOPMENT, 2011-2018 ($ MILLIONS) 153

To order this report: Drug_Discovery_and_Development Industry: Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery

Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs